Clinical significance of the isolation of *Candida* species from hospitalized patients

Yankee C. Magalhães¹, Maria Rosa Q. Bomfim², Luciane C. Melônio¹, Patricia C.S. Ribeiro¹,²,³, Lécia M. Cosme⁴, Cristianne R. Rhoden¹, Sirlei G. Marques¹,²,³

¹Laboratório Cedro, São Luís, MA, Brazil.
²Universidade CEUMA, São Luís, MA, Brazil.
³Hospital Universitário, Universidade Federal do Maranhão, São Luís, MA, Brazil.
⁴Laboratório Central de Saúde Pública do Maranhão, São Luís, MA, Brazil.

Submitted: November 2, 2012; Approved: June 6, 2014.

Abstract

In this study, we isolated and phenotypically identified 108 yeast strains from various clinical specimens collected from 100 hospitalized patients at three tertiary hospitals in São Luís-Maranhão, Brazil, from July to December 2010. The isolates were analyzed for their susceptibility to four of the most widely used antifungal agents in the surveyed hospitals, amphotericin B, fluconazole, 5-flucytosine and voriconazole. The species identified were *Candida albicans* (41.4%), *Candida tropicalis* (30.1%), *C. glabrata* (7.4%), *Candida parapsilosis* (5.5%), *Candida krusei* (4.6%), *Cryptococcus neoformans* (4.6%), *Trichosporon* spp. (3.7%), *Candida norvegensis* (0.9%), *Rhodotorula glutinis* (0.9%) and *Pichia farinosa* (0.9%). A higher isolation rate was observed in the following clinical specimens: urine (54 isolates; 50%), respiratory tract samples (21 isolates; 19.4%) and blood (20 isolates; 18.6%). *Candida albicans* isolates were 100% sensitive to all antifungal agents tested, whereas *Candida krusei* and *Cryptococcus neoformans* displayed intermediate resistance to 5-flucytosine, with Minimal Inhibitory Concentration (MIC) values of 8 mg/mL and 16 mg/mL, respectively. Both strains were also S-DD to fluconazole with an MIC of 16 mg/mL. *C. tropicalis* was resistant to 5-flucytosine with an MIC of 32 μg/mL. This study demonstrates the importance of identifying the yeast species involved in community and nosocomial infections.

Key words: fungal infections, susceptibility profile, nosocomial infections.

Introduction

*Candida* and *Cryptococcus* fungi, which belong to the *Saccharomycetaceae* and *Tremellaceae* families, respectively are the most medically important yeast species (Hazan and Howell, 2007). There are over 200 known species of the genus *Candida*, but only a relatively small number of *Candida* are pathogenic to humans (Chander, 2009). A number of species have been isolated from humans, including *C. albicans*, *C. parapsilosis*, *C. tropicalis*, *C. glabrata*, *C. krusei*, *C. lusitaniae*, *C. guilliermondii*, *C. dubliniensis*, *C. famata*, *C. utilis*, *C. lipolytica*, *C. norvegensis*, *C. inconspicua*, *C. kefyr*, *C. rugosa*, *C. haemulonii*, *C. viswanathii* and *C. albicans* var. *stellatoidea* (Basetti et al., 2007; Hattori et al., 2009; Barbérdo and Sgarbi, 2010).

The incidence of fungal infections due to *Candida* spp. has been increasing in recent years (Severo et al., 2009; Binder and Lass-Flörl, 2011), profoundly affecting public health (Vandeputte et al., 2012). Substantial morbidity and mortality are associated with fungal infections in various patient groups (Gudlaugsson et al., 2003). Currently, *Candida* yeasts are the most common opportunistic pathogens in humans and are associated with almost 80% of all nosocomial fungal infections (Pappas et al., 2004; Kim and Sudbery, 2011). However, cases of cryptococcosis have increased sharply during the past two decades as a result of the AIDS epidemic, cancer chemotherapy, and...
Cryptococcosis is a systemic mycosis caused by two species of the encapsulated basidiomycetes, Cryptococcus neoformans and C. gattii, which cause infection in immunocompromised individuals and in immunologically normal hosts, respectively (Sionov et al., 2009). Because most fungal infections are opportunistic, the frequency of these infections in different countries varies considerably (Xavier et al., 2008). Moreover, factors inherent to the host can lead to the establishment of infection (Pappas et al., 2004). In this context, opportunistic fungal pathogens, such as Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus, have accounted for most of the mycotic infections in immunocompromised individuals, and these infections often become life-threatening (Pfaller et al., 2007; Xavier et al., 2008; Karkowska-Kuleta et al., 2009).

Difficulties in diagnosing fungal infections early have resulted in the lack of timely and appropriate antifungal therapies to effectively treat fungal infections (Pappas et al., 2004). The incidence of fungal infection has risen, especially in ill patients with the greatest risk, and the list of potential pathogens previously considered components of the human microbiota has expanded (Fridkin, 2005). Thus, it is extremely important to monitor fungal infections, especially in patients in intensive care units, patients with degenerative and neoplastic diseases, transplant recipients, premature newborns and patients with AIDS (Xavier et al., 2008; Karkowska-Kuleta et al., 2009; Kim and Sudbery 2011).

The aims of this study were to analyze the prevalence of yeast species isolated from various clinical materials taken from patients hospitalized in three hospitals from São Luís-MA and to determine the in vitro activity of four antifungal agents, amphotericin B (AMB), fluconazole (FCZ), 5-flucytosine (5-FC) and voriconazole (VCZ).

Materials and Methods

Ethical aspects

This study was approved by the Research Ethics Committee, University Center of Maranhão (UNICEUMA), under Protocol No. 0014/10.

Clinical samples

In this study, we used 100 clinical samples collected from patients at one private hospital “A” (n = 37) and two public hospitals “B” (n = 31) and “C” (n = 32) in São Luís, Maranhão, Brazil, from July to December 2010. All patients were treated at tertiary hospitals. For the isolation, fungi were cultured in media containing mycobiotic agar and Sabouraud Dextrose Agar (Difco Laboratories, Detroit, MI, USA). The plates were incubated at 28 °C or 37 °C for 1 to 25 days and examined daily until fungal growth was observed.

An automated method (Vitek-2 Compact bioMérieux, Marcy-L’Etoile, France) was used to identify the fungal isolates. The inoculum was diluted with 3 mL of physiological saline 0.45% fungal colony. Samples with a McFarland standard number of two were used with the DensiChek-bioMérieux (Vitek). These standardized suspensions were applied to the identification cards, which were then sealed and subjected to biochemical reading by an optical sensor. We used the YST card (Yeast identification) (bioMérieux) to determine the gender and species of the yeast isolates. For the blood and cerebrospinal fluid (CSF) cultures, the BACT ALERT automated system was used (bioMérieux). Additionally, samples were identified using traditional phenotypic methods, such as zymography, auxanography, proof of chlamydospores and filamentation. For the Cryptococcus strains, we used a urease test, a thermotolerance test at 35 °C, a test for sensitivity to cycloheximide and staining of the capsule with India ink.

To investigate antifungal susceptibility, minimal inhibitory concentrations (MICs) were calculated using 180 μL of standardized inoculum diluted in a tube containing 3 mL of saline to 0.45%; the sample was then applied to the AST-YS01 card (bioMérieux). We tested the following antifungal drugs: amphotericin B (AMB), fluconazole (FCZ), 5-flucytosine (5-FC) and voriconazole (VCZ). The analysis and interpretation of the data were performed according to the standards of the Clinical and Laboratory Standards Institute M27-A3 and M27-S3 (CLSI, 2008a; 2008b). Yeasts that belonged to repeated biological samples from the same patient were excluded. The following reference isolates from the American Type Culture Collection (ATCC) were used as controls: C. neoformans ATCC MYA-4566, Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019.

Statistical analysis

To compare the activity of the antifungal drugs against the fungi tested, we determined the maximum and minimum MIC values, the geometric mean (MedGeo) and the MIC values at which 50% (MIC50) and 90% (MIC90) of the isolate population was inhibited. The data were analyzed using Epi Info version 6.0 (Dean et al., 1994).

Results

From the 100 different clinical specimens used in this study, we identified 2,004 microorganisms consisting of 1,896 (94.6%) bacterial strains and 108 (5.4%) yeast strains isolated from Hospital A [1,045 (52.1%) bacteria and 42 (2.1%) yeast], Hospital B [355 (17.7%) bacteria and 32 (1.6%) yeast] and Hospital C [496 (24.8%) bacteria and 34 (1.7%) yeast]. The majority of yeast species were isolated from female patients (56%; 44% from males), with the
most affected age group being over 60 years of age (51%). These patients were predominantly admitted to the Intensive Care Unit (66%).

Evaluation of the frequency of yeast infection in each hospital indicated that there was a large number of isolates at Hospital A (39%) compared with Hospitals B (29.6%) and C (31.4%); of these isolates, C. albicans was the most prevalent species. The number of non-albicans Candida strains evaluated from the three hospitals represented 48.1% of the total sample (Table 1).

Table 2 presents data showing that 89.8% of all the isolates (97 isolates) belonged to the Candida genus, whereas the others were Cryptococcus, Pichia, Rhodotorula and Trichosporon species, totaling 10.2% of the isolates. We identified the following species: 45 C. albicans (41.7%), 8 C. glabrata (7.5%), 1 C. norvegensis (0.9%), 5 C. krusei (4.6%), 6 C. parapsilosis (5.6%), 32 C. tropicalis (29.7%), 5 Cryptococcus neoformans (4.6%), 1 Pichia farinosa (0.9%), 1 Rhodotorula glutinis (0.9%) and 4 Trichosporon spp. (3.7%).

Yeasts were detected mainly from urine (54, 50%), the respiratory tract (21, 19.4%), blood (20, 18.6%), the catheter tip (7, 6.4%) and CSF (2, 1.8%), and the remaining four specimens (3.7%) were from wound secretions (1, 0.9%), wound fragments (1, 0.9%), vaginal secretions (1, 0.9%) and stools (1, 0.9%). The most predominant species in the urine samples were C. albicans (24, 22.2%), C. tropicalis (20, 18.6%) and Candida glabrata (4, 3.7%). The most predominant clinical specimens from the respiratory tract were C. albicans (13, 12.1%) and C. tropicalis (4, 3.7%). C. tropicalis was the most prevalent species isolated from the blood (5, 4.6%), with the same isolation rate (3.7%) as C. albicans and C. parapsilosis. Notably, three C. neoformans strains were isolated from blood samples and two from the CSF (Table 2).

Table 3 shows the susceptibility of the fungal isolates to the antifungals tested in this study. All of the C. albicans strains were susceptible to all four antifungals, AMB, FCZ, 5-FC and VCZ. These yeast strains exhibited an MIC50 and MIC90 of 1 μg/mL for AMB, 5-FC and FCZ and lower MIC50 and MIC90 values (0.12 mg/mL) for VCZ. Of the five C. krusei strains isolated, two showed an MIC of 8 mg/mL and appeared to be susceptible dependent upon dose (S-DD) to FCZ at an MIC of 16 mg/mL. Of the 32 C. tropicalis strains, only two were resistant to 5-FC with a MIC of 32 mg/mL, corresponding to 6.25% of the isolates. All isolates exhibited smaller MIC50 and MIC90 values for VCZ (0.12 mg/mL), whereas these values were higher for FCZ (1 and 2 mg/mL, respectively) compared with VCZ (Table 3).

A C. neoformans strain isolated from cerebrospinal fluid and another from blood exhibited an MIC of 16 / mL for 5-FC and FCZ. This result was confirmed using an epsilometric E-test. Since no interpretive breakpoints have been determined for C. neoformans we used those considered in document M27-A3 CLSI (CLSI, 2008b) for Candida.

Discussion

Candida species are ubiquitous fungi that include the most common fungal pathogens that cause superficial and invasive diseases in humans (Chander et al., 2009; Fisher et al., 2011). Candiduria is rarely present in healthy individuals but is commonly found in hospitalized patients, especially those with multiple predisposing factors, including structural abnormalities of the kidney, diabetes mellitus, indwelling urinary catheters, immunosuppression and exposure to antimicrobials (Trofa et al., 2008; Fisher et al., 2011). In this study, 89.9% of the clinical isolates obtained from three different hospitals (A, B and C) were of the Candida genus. C. albicans was the most prevalent species

Table 1 - Frequency of yeast species isolated from clinical specimens taken from patients hospitalized in public and private hospitals in São Luís - MA from July to December 2010.

| Species isolated        | Hospital A | Hospital B | Hospital C | Total isolates |
|-------------------------|------------|------------|------------|----------------|
|                         | Isolates n° (%) |           |            |                |
| Candida albicans        | 17 (15.8)  | 16 (14.8)  | 12 (11.1)  | 45 (41.7)      |
| Candida glabrata        | 2 (1.85)   | 4 (3.7)    | 2 (1.85)   | 8 (7.4)        |
| Candida krusei          | 2 (1.85)   | 2 (1.85)   | 1 (0.9)    | 5 (4.6)        |
| Candida norvegensis     | 0 (0.0)    | 1 (0.9)    | 0 (0.0)    | 1 (0.9)        |
| Candida parapsilosis    | 2 (1.85)   | 0 (0.0)    | 4 (3.7)    | 6 (5.6)        |
| Candida tropicalis      | 12 (11.1)  | 10 (9.3)   | 10 (9.3)   | 32 (29.7)      |
| Cryptococcus neoformans| 3 (2.8)    | 1 (0.9)    | 1 (0.9)    | 5 (4.6)        |
| Pichia farinose         | 0 (0.0)    | 0 (0.0)    | 1 (0.9)    | 1 (0.9)        |
| Rhodotorula glutinis    | 1 (0.9)    | 0 (0.0)    | 0 (0.0)    | 1 (0.9)        |
| Trichosporon spp.       | 2 (1.85)   | 0 (0.0)    | 2 (1.85)   | 4 (3.7)        |
| Total                   | 41 (37.9)  | 34 (31.5)  | 33 (30.6)  | 108 (100%)     |
in the urinary tract, respiratory tract and catheter tip, followed by \textit{C. tropicalis} and \textit{C. glabrata}. These results are consistent with the literature showing that \textit{C. albicans} is the yeast most commonly isolated from the urinary tract and is responsible for approximately 50% to 70% of cases of candiduria, followed by \textit{C. glabrata} (5% to 33%) and other species of non-albicans yeasts (8% to 28%) (Kauffman, 2005; Trofa et al., 2008; Moen et al., 2009). Surveys conducted in Brazil also show that the three most prevalent species isolated from the urine of hospitalized patients were \textit{C. albicans} (35.5% to 70%), \textit{C. tropicalis} (4.6% to 52.5%) and \textit{C. glabrata} (7% to 8.8%) (Binelli et al., 2006; Furlaneto et al., 2011).

As a common and widespread opportunistic yeast pathogen, \textit{Candida} species account for 8-10% of all nosocomial bloodstream infections (Lundston and Sobel, 2001; Colombo et al., 2002; Franca et al., 2008). In this study, \textit{C. tropicalis} was the most prevalent strain found in blood samples (4.6%), whereas \textit{C. albicans} and \textit{C. parapsilosis} were isolated from 3.7% of samples. These data are consistent with previously published results showing that \textit{C. glabrata}, \textit{C. parapsilosis}, \textit{C. tropicalis}, and other non-albicans \textit{Candida} (NAC) species have been recovered with increasing frequency (Krcmery and Barnes, 2002; Perea and Patterson, 2002). It is therefore interesting that \textit{C. tropicalis} infections have increased since 2003, whereas infections due to all other non-albicans species have been decreasing (Yap et al., 2009). In a study performed at the University Hospital of the Federal University of Mato Grosso do Sul (HU-UFMS), NAC samples were recovered more frequently from blood culture samples than \textit{C albicans} and \textit{C parapsilosis} (Xavier et al., 2008). It was also demonstrated that 39% of surveyed blood cultures harbored NAC (Hanh et al., 2008).

In this study, five cases of cryptococcosis were detected in three blood samples and in two cerebrospinal fluid samples from patients at three different hospitals in São Luís, Maranhão State, Brazil. We observed an incidence of 4.6% of cryptococcosis in immunocompromised patients without HIV infection. Our data are consistent with previous studies showing that this yeast is predominantly an opportunistic agent that causes infection in adults with acquired immunodeficiency syndrome (AIDS), although it has been identified in other types of immunocompromised conditions (Chayakulkeeree and Perfect, 2006; Kiertiburanakul et al., 2006; Pfaller et al., 2007). Notably, infections due to \textit{Cryptococcus} in hospitalized patients have increased in recent years, and more than 80% of cryptococcosis cases worldwide are associated with HIV infection (Sionov et al., 2009).

Most \textit{Candida} species were sensitive to all four antifungals tested; however, two \textit{C. tropicalis} isolates were resistant to 5-FC. In addition, two strains of \textit{Candida kruziei} exhibited an intermediate response to 5-FC and another strain was S-DD to FCZ. These data are consistent with a prospective surveillance study conducted in 16 U.S. hospitals for three years, in which \textit{C. tropicalis}, \textit{C. parapsilosis} and \textit{C. kruziei} together accounted for approximately 20% of opportunistic infections. \textit{Candida tropicalis} showed the highest rate of in vitro resistance to 5-FC among \textit{Candida} species (Diekema et al., 2006). Epidemiological studies have identified risk factors associated with antifungal drug resistance (Canuto and Rodero, 2002). In the present study, we observed several resistant strains; only one \textit{C. kruziei} isolate demonstrated dose-dependent susceptibility to FCZ, but all \textit{C. glabrata} strains were susceptible to this antifungal action.

### Table 2 - Distribution of 108 yeast isolates identified in cultures of different biological materials evaluated during July to December 2010.

| Yeasts isolated     | Urine (Nº. (%)) | Blood (Nº. (%)) | R.T. (Nº. (%))* | Catheter tip (Nº. (%)) | Liquor (Nº. (%)) | Others (Nº. (%))** | N° total isolates (Nº. (%)) |
|---------------------|-----------------|----------------|----------------|------------------------|----------------|------------------|------------------------|
| \textit{Candida albicans} | 24 (22.2)       | 4 (3.7)        | 13 (12.1)      | 2 (1.85)               | 0 (0.0)        | 2 (1.85)         | 45 (41.7)              |
| \textit{Candida glabrata}  | 4 (3.7)         | 2 (1.85)       | 1 (0.9)        | 1 (0.9)                | 0 (0.0)        | 0 (0.0)          | 08 (7.4)               |
| \textit{Candida norvegensis} | 1 (0.9)        | 0 (0.0)        | 0 (0.0)        | 0 (0.0)                | 0 (0.0)        | 0 (0.0)          | 01 (0.9)               |
| \textit{Candida krusei}    | 2 (1.85)        | 1 (0.9)        | 1 (0.9)        | 1 (0.9)                | 0 (0.0)        | 0 (0.0)          | 05 (4.6)               |
| \textit{Candida parapsilosis} | 1 (0.9)        | 4 (3.7)        | 0 (0.0)        | 1 (0.9)                | 0 (0.0)        | 0 (0.0)          | 06 (5.6)               |
| \textit{Candida tropicalis} | 20 (18.6)      | 5 (4.6)        | 4 (3.7)        | 1 (0.9)                | 0 (0.0)        | 2 (1.85)         | 32 (29.7)              |
| \textit{Cryptococcus neoformans} | 0 (0.0)      | 3 (2.8)        | 0 (0.0)        | 0 (0.0)                | 2 (1.85)        | 0 (0.0)          | 05 (4.6)               |
| \textit{Pichia farinosa}   | 0 (0.0)         | 1 (0.9)        | 0 (0.0)        | 0 (0.0)                | 0 (0.0)        | 0 (0.0)          | 01 (0.9)               |
| \textit{Rhodotorula glutinis} | 0 (0.0)       | 0 (0.0)        | 1 (0.9)        | 0 (0.0)                | 0 (0.0)        | 0 (0.0)          | 01 (0.9)               |
| \textit{Trichosporon spp.} | 2 (1.85)        | 0 (0.0)        | 1 (0.9)        | 1 (0.9)                | 0 (0.0)        | 0 (0.0)          | 04 (3.7)               |
| Total                 | 54 (50.0)       | 20 (18.6)      | 21 (19.4)      | 7 (6.4)                | 2 (1.85)        | 4 (3.7)          | 108 (100)              |

*Respiratory Tract.
**Others (Wound secretions, wound fragments, vaginal secretions, and stools of patients).
Table 3 - In vitro antifungal susceptibility and the MIC50 and MIC90 of yeasts isolated from patients admitted to three hospitals in São Luís, MA, from July to December 2010.

| Antifungal agents/yeasts isolated | Isolates (n°) | MIC (µg/mL) | Range | MIC<sub>50</sub> | MIC<sub>90</sub> |
|----------------------------------|---------------|-------------|-------|------------------|------------------|
|                                  |               |             |       |                  |                  |
| **Anfotericina B**               |               |             |       |                  |                  |
| Candida albicans                 | 45            | 0.5 - 2     | 1     | 1                | 1                |
| Candida glabrata                 | 8             | 0.5 - 2     | ND    | ND               | ND               |
| Candida krusei                   | 5             | 0.5 - 1     | ND    | ND               | ND               |
| Candida norvegensis              | 1             | 0.5         | ND    | ND               | ND               |
| Candida parapsilosis             | 6             | 0.5         | ND    | ND               | ND               |
| Candida tropicalis               | 32            | 0.25 - 0.5  | 0.5   | 0.5              | 0.5              |
| Cryptococcus neoformans          | 5             | 0.5 - 1     | ND    | ND               | ND               |
| Pichia farinosa                  | 1             | ND          | ND    | ND               | ND               |
| Rhodotorula glutinis             | 1             | ND          | ND    | ND               | ND               |
| Trichosporon spp.                | 4             | ND          | ND    | ND               | ND               |
| **Fluconazol**                   |               |             |       |                  |                  |
| Candida albicans                 | 45            | 1           | 1     | 1                | 1                |
| Candida glabrata                 | 8             | 2 - 4       | ND    | ND               | ND               |
| Candida krusei                   | 5             | 8 - 16      | ND    | ND               | ND               |
| Candida norvegensis              | 1             | 4           | ND    | ND               | ND               |
| Candida parapsilosis             | 6             | 2           | ND    | ND               | ND               |
| Candida tropicalis               | 32            | 1 - 4       | 1     | 2                |                  |
| Cryptococcus neoformans          | 5             | 1 - 16      | ND    | ND               | ND               |
| Pichia farinosa                  | 1             | ND          | ND    | ND               | ND               |
| Rhodotorula glutinis             | 1             | ND          | ND    | ND               | ND               |
| Trichosporon spp.                | 4             | ND          | ND    | ND               | ND               |
| **5-Flucytosine**                |               |             |       |                  |                  |
| Candida albicans                 | 45            | 1           | 1     | 1                | 1                |
| Candida glabrata                 | 8             | 1           | ND    | ND               | ND               |
| Candida krusei                   | 5             | 4 - 8       | ND    | ND               | ND               |
| Candida norvegensis              | 1             | 2           | ND    | ND               | ND               |
| Candida parapsilosis             | 6             | 1           | ND    | ND               | ND               |
| Candida tropicalis               | 32            | 1 - 32      | 1     | 1                |                  |
| Cryptococcus neoformans          | 5             | 1 - 16      | ND    | ND               | ND               |
| Pichia farinosa                  | 1             | ND          | ND    | ND               | ND               |
| Rhodotorula glutinis             | 1             | ND          | ND    | ND               | ND               |
| Trichosporon spp.                | 4             | ND          | ND    | ND               | ND               |
| **Voriconazol**                  |               |             |       |                  |                  |
| Candida albicans                 | 45            | 0.12        | 0.12  | 0.12             | 0.12             |
| Candida glabrata                 | 8             | 0.12 - 1    | ND    | ND               | ND               |
| Candida krusei                   | 5             | 0.12        | ND    | ND               | ND               |
| Candida norvegensis              | 1             | 0.12        | ND    | ND               | ND               |
| Candida parapsilosis             | 6             | 0.12        | ND    | ND               | ND               |
| Candida tropicalis               | 32            | 0.12        | 0.12  | 0.12             | 0.12             |
| Cryptococcus neoformans          | 5             | ND          | ND    | ND               | ND               |
| Pichia farinosa                  | 1             | ND          | ND    | ND               | ND               |
| Rhodotorula glutinis             | 1             | ND          | ND    | ND               | ND               |
| Trichosporon spp.                | 4             | ND          | ND    | ND               | ND               |

Legend: MIC = minimum inhibitory concentration, MIC90 = minimum inhibitory concentration for 90% of the isolates and MIC50 = minimum inhibitory concentration for 50% of the isolates, ND = Not determined.
Increased use of FCZ has led to the development of resistance in *Candida* spp., particularly *C. glabrata* and *C. krusei* (Colombo et al., 2002). Some NAC species are inherently or secondarily resistant to fluconazole, including 75% of *C. krusei* isolates, 35% of *C. glabrata*, 10-25% of *C. tropicalis* and *C. lusitaniae* (Krcmery and Barnes, 2002; Lewis, 2009). Some studies have reported failures in prophylaxis and treatment of *C. glabrata, C. krusei* and *Trichosporon* spp. with fluconazole (Colombo et al., 2002; Paul et al., 2007).

A strain of *C. neoformans* isolated from CSF has a higher MIC value for FCZ (16 mg/mL). This patient had already been treated with FCZ for 30 days but was not responding to the established therapy and subsequently died. FCZ has been the drug of choice for treating fungal infections and has been widely used to manage cryptococcosis in AIDS patients, but its prolonged use has led to the emergence of FCZ-resistant strains (Warnock, 2007; Sobel et al., 2011). According to Consensus in Cryptococcosis (2008), testing for antifungal susceptibility can be useful in the clinic, where these tests are performed only in cases of treatment failure or in patients with frequent relapses who received repeated cycles of antifungal treatment with azoles or amphotericin B.

In this study, all *Candida* strains were susceptible to amphotericin B. Resistance to AMB appeared to be uncommon among isolates of *C. albicans, C. tropicalis* and *C. parapsilosis*, but there are data suggesting that resistant strains of *C. glabrata* and *C. krusei* exist (Krcmery and Barnes, 2002; Antunes et al., 2004). Randomized, double-blind studies with adults and/or children with a liposomal AMB demonstrated efficacy of this drug in invasive fungal infections, including invasive candidiasis, candidemia, invasive fungal infection aspergillosis, histoplasmosis and cryptococcal meningitis (Moran et al., 2011).

The antifungal agent voriconazole showed excellent activity against the yeast isolates evaluated in this study. Notably, VCZ has the potential to be effective against some strains that are resistant to fluconazole (Paul et al., 2007).

Using the automated method (Vitek-2 Compact bioMérieux, Marcy-L’Etoile, France), the MIC results for the three antifungal agents were highly reproducible, even in comparison with results attained using the reference method for analyzing broth microdilutions that has been tested in three U.S. laboratories with 426 isolates of *Candida* spp. (Severo et al., 2009). Our study showed a high level of reproducibility for the three antifungal agents: VCZ (98.1%), 5-FC (99.3%) and AMB (100%). The authors also suggest that, in addition to the high level of reproducibility, the automated system provides rapid results that represent a major step towards optimizing treatments for invasive *Candida* infections (Severo et al., 2009).

The results of our study reinforce the importance of identifying *Candida* species, defining their antifungal susceptibility profiles and determining the prevalence of these infections in the hospital environment to improve treatment options for patients with invasive fungal infections. Therefore, the ability to accurately identify and periodically survey the susceptibility profile of yeasts to antifungal agents is crucial for monitoring the development of resistance and for assisting health professionals in delineating guidelines for appropriate use of these medicines.

Acknowledgments

The authors thank to Fundação de Amparo à Pesquisa e Desenvolvimento Científico do Maranhão (FAPEMA) and Dr. Elie Georges Hachem-Laboratório Cedro São Luís, MA.

References

Antunes AG, Pasqualotto AC, Dias MC et al. (2004) Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev Soc Bras Med Trop 46:239-241.

Barbedo LS, Sgarbi DB (2010) Candidiasis. J Bras Doencas Sex Transm 22:22-38.

Basetti M, Trecarichi EM, Righi E et al. (2007) Incidence, risk factors and predictors of outcome of candidemia. Survey in 2 Italian hospitals. Diag Microbiol Infect Dis 58:325-331.

Binder U, Lass-Flörl C (2011) Epidemiology of invasive fungal infections in the Mediterranean area. Mediterr J Hematol Infect Dis 3:e20110016.

Binelli CA, Moretti ML, Assis RS et al. (2006) Investigation of the possible association between nosocomial candiduria and candidaemia. Clin Microb Infec 12:538-543.

Canuto MM, Rodero FG (2002) Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2:550-563.

Chayakulkeeree M, Perfect JR (2006) Cryptococcosis. Infect Dis Clin North Am 20:507-544.

Clinical and Laboratory Standards Institute (2008a) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard-Third Edition. CLSI Document M27-A3, (ISBN 1-56238-666-2). Wayne, Pennsylvania.

Clinical and Laboratory Standards Institute (2008b) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Supplement. NCCLS document M27-S3. Wayne, Pennsylvania.

Colombo AL, Matta D, Almeida LP (2002) Fluconazole susceptibility of Brazilian *Candida* isolates assessed by a disk diffusion method. Braz J Infect Dis 6:118-23.

Consensus em Cryptococose (2008) Guidelines in Cryptococcosis Rev Soc Bras Med Trop 41:524-544.

Dean AG, Dean JA, Coulombier D et al. (1994) Epi Info, Version 6: a word processing, database, and statistics program for epidemiology on microcomputers.

Diekema DJ, Messer SA, Brueggermann AB et al. (2002) Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. J Clin Microbiol 40:1298-1302.

Chander J (2009) Textbook of Medical Mycology. 3rd Edition. Mehta Publishers, Pune, pp 266-283.
Fisher JF, Kavanagh K, Sobel JD et al. (2011) Candida urinary tract infection: pathogenesis. Clin Infect Dis 52:437-51.
França JC, Ribeiro CE, Queiroz-Telles F (2008) Candidemia in a Brazilian tertiary care hospital: incidence, frequency of different species, risk factors and antifungal susceptibility. Rev Soc Bras Med Trop 41:23-8.
Fridkin SK (2005) The changing face of fungal infections in health care settings. Clin Infect Dis 41:1455-1460.
Furlaneto MC, Rota JF, Quesada RM et al. (2011) Species distribution and in vitro fluconazole susceptibility of clinical Candida isolates in a Brazilian tertiary-care hospital over a 3-year period. Rev Soc Bras Med Trop 44:595-599.
Gudlaugsson O, Gillespie S, Lee K et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172-1177.
Hanh RC, Prado KS, Dias LB et al. (2008) Candidíase em um hospital universitário mato-grossense: incidência, frequência das diferentes espécies e susceptibilidade aos antifúngicos. Prática Hospitalar 10:69-72.
Hattori H, Tanaka R, Chibana H et al. (2009) Improvement of the repetitive sequence-based identification and genotyping of Candida albicans using ALT-specific primers. Jpn J Infect Dis 62:215-219.
Hazen KC, Howell AS (2007) Candida, Cryptococcus, and other Yeasts of medical importance. In: Murray PR, Baron EJ, Jorgensen JH et al. (eds) Manual of Clinical Microbiology. ASM press, Washington, pp. 1762-1788.
Karkowska-Kuleta J, Rapala-Kozik M, Kozik A (2009) Fungi pathogenic to humans: molecular base of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigates. Acta Biochim Polonica 56:211-224.
Kauffman CA (2005) Candiduria. Clin Infect Dis 41:371-376.
Kiertiburanakul SS, Wirojtananugoon SS, Pracharktam RR et al. (2006) Cryptococcosis in human immunodeficiency virus-negative patients. Int J Infect Dis 10:72-78.
Kim J, Sudbery P (2011) Candida albicans: a Major Human Fungal Pathogen. J Microbiol 49:171-177.
Kremery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50:243-260.
Lewis RE (2009) Overview of the changing epidemiology of candidemia. Curr Med Res Opin 25:1732-1740.
Lundston T, Sobel J (2001) Nosocomial Candidurí: A Review. Clin Infect Dis 32:1602-1607.
Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392.
Moran GP, Coleman DC, Sullivan DJ (2011) Comparative Genomics and the Evolution of Pathogenicity in Human Pathogenic Fungi. Eukaryot Cell 10:34-42.
Pappas PG, Rex JH, Sobel JD et al. (2004) Guidelines for Treatment of Candidiasis. Clin Infect Dis 38:161-189.
Paul N, Mathai E, Abraham OC et al. (2007) Factors associated with candiduria and related mortality. J Infect 55:450-455.
Perea S, Patterson TF (2002) Antifungal Resistance in Pathogenic Fungi. Clin Infect Dis 35:1073-1080.
Pfaller MA, Diekema DJ, Procop GW et al. (2007) Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing Amphotericin B, Fluconysine, and Voriconazole against Candida spp. J Clin Microbiol 45:3522-3528.
Severo CB, Gazzoni AF, Severo LC (2009) Pulmonary cryptococcosis. J Bras Pneumol 35:1136-1144.
Sionov E, Chang YC, Garaffo HM et al. (2009) Heteroresistance to Fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 53:2804-2815.
Sobel JD, Fischer JF, Kauffman CA et al. (2011) Candida urinary tract infections - Epidemiology. Clin Infect Dis 52:433-436.
Trofa D, Gácsér A, Nosanchuk J (2008) Candida parapsilosis, an Emerging Fungal Pathogen. Clin Microbiol Rev 21:606-662.
Vandeputte P, Ferrari S, Coste AT (2012) Antifungal Resistance and New Strategies to Control Fungal Infections. Int J Microbiol 2012:713687.
Warnock DW (2007) Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 48:1-12.
Xavier PC, Chang MR, Nunes MO et al. (2008) Candidemia neonatal, em hospital público do Mato Grosso do Sul. Rev Soc Bras Med Trop 41:459-463.
Yap HY, Kwok KM, Gomersall CD et al. (2009). Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med 15:255-261.

Associate Editor: Carlos Pelleschi Taborda

All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License CC BY-NC.